天士力 (600535.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

10.6x

EV/EBITDA

12.4x

Market Cap

CNY 22.14B

MomentumView details →

1D Return

−1.00%

YTD Return

−2.26%

RSI (14)

41.6

ValuationView details →

P/E (Fwd)

10.6x

EV/EBITDA

12.4x

Market Cap

CNY 22.14B

RSI (14)

41.6

MomentumView details →

1D Return

−1.00%

YTD Return

−2.26%

ProfitabilityView details →

Gross Margin

68.04%

Net Margin

13.91%

EBITDA Margin

21.80%

ROE (TTM)

9.09%

ROA (TTM)

7.40%

Asset Turnover

0.54x

GrowthView details →

Revenue YoY

−1.86%

EPS YoY

+19.75%

FCF YoY

+45.27%

Revenue CAGR 3Y

−1.57%

EPS CAGR 3Y

+1.38%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.23

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.08x

Current Ratio

3.72x

Quick Ratio

3.09x

Div Yield

2.10%

Div Rate

CNY 0.31

Div Growth 1Y

−75.61%

Financials snapshotView financials →

Revenue (TTM)

8.35B

Net Income (TTM)

1.16B

Op. CF (TTM)

2.25B

Next earningsOct 26, 2026 →

Latest newsMore news →

Tasly's net profit attributable to shareholders increased by 15.23% in the first half of 2026 despite a slight revenue decline, with 10 products newly included in the 2026 National Essential Medicines List.4d ago

Tasly Pharmaceutical Group announced that 10 of its products, including two exclusive products Jinghua Weikang Jiaowan and Shaoma Zhijing Granules, were newly included in the 2026 National Essential Medicines List.14d ago

Similar companies

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited00874.HK 济川药业600566.SH Aprogen Biologics Inc.003060.KS 哈药股份600664.SH 华海药业600521.SH The United Laboratories International Holdings Limited03933.HK Find similar companies →

Latest newsMore news →

Tasly's net profit attributable to shareholders increased by 15.23% in the first half of 2026 despite a slight revenue decline, with 10 products newly included in the 2026 National Essential Medicines List.4d ago Tasly Pharmaceutical Group announced that 10 of its products, including two exclusive products Jinghua Weikang Jiaowan and Shaoma Zhijing Granules, were newly included in the 2026 National Essential Medicines List.14d ago Tasly Pharmaceutical Group reported first-half revenue of 4.20 billion RMB and net profit of 892.7 million RMB.14d ago